Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to Post Q3 2024 Earnings of $1.39 Per Share, Leerink Partnrs Forecasts

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Leerink Partnrs boosted their Q3 2024 earnings per share estimates for Sarepta Therapeutics in a research note issued on Wednesday, May 1st. Leerink Partnrs analyst J. Schwartz now expects that the biotechnology company will earn $1.39 per share for the quarter, up from their previous estimate of $1.37. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.14 per share. Leerink Partnrs also issued estimates for Sarepta Therapeutics’ Q4 2024 earnings at $4.20 EPS, FY2024 earnings at $5.88 EPS and FY2025 earnings at $11.58 EPS.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.84. The company had revenue of $413.50 million during the quarter, compared to analyst estimates of $375.52 million. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. The firm’s revenue for the quarter was up 63.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.44) earnings per share.

Other research analysts have also issued reports about the company. BMO Capital Markets started coverage on Sarepta Therapeutics in a research report on Wednesday, January 31st. They set an “outperform” rating and a $170.00 price target for the company. Cantor Fitzgerald restated a “neutral” rating and set a $128.00 price target on shares of Sarepta Therapeutics in a research report on Thursday. Citigroup raised their price target on Sarepta Therapeutics from $160.00 to $172.00 and gave the stock a “buy” rating in a research report on Thursday, February 29th. Royal Bank of Canada increased their price objective on Sarepta Therapeutics from $151.00 to $157.00 and gave the company an “outperform” rating in a research note on Thursday, February 29th. Finally, JPMorgan Chase & Co. reduced their price objective on Sarepta Therapeutics from $177.00 to $175.00 and set an “overweight” rating on the stock in a research note on Friday. Four equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $160.60.

Sarepta Therapeutics Trading Up 2.3 %

Shares of Sarepta Therapeutics stock opened at $133.66 on Friday. The firm has a market capitalization of $12.63 billion, a price-to-earnings ratio of 1,215.09 and a beta of 0.95. Sarepta Therapeutics has a fifty-two week low of $55.25 and a fifty-two week high of $159.89. The company has a debt-to-equity ratio of 1.18, a quick ratio of 3.45 and a current ratio of 4.05. The stock has a 50 day moving average of $125.63 and a 200 day moving average of $110.81.

Insiders Place Their Bets

In related news, insider Bilal Arif sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $128.84, for a total value of $257,680.00. Following the sale, the insider now owns 26,836 shares in the company, valued at approximately $3,457,550.24. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Sarepta Therapeutics news, insider Bilal Arif sold 2,000 shares of the stock in a transaction on Friday, March 1st. The stock was sold at an average price of $128.84, for a total transaction of $257,680.00. Following the transaction, the insider now owns 26,836 shares of the company’s stock, valued at approximately $3,457,550.24. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Ian Michael Estepan sold 1,200 shares of the stock in a transaction on Friday, March 1st. The stock was sold at an average price of $128.30, for a total value of $153,960.00. Following the transaction, the chief financial officer now directly owns 39,114 shares in the company, valued at approximately $5,018,326.20. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 22,096 shares of company stock worth $2,739,419. Company insiders own 7.40% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Howland Capital Management LLC purchased a new position in shares of Sarepta Therapeutics in the 1st quarter worth $211,000. Riggs Asset Managment Co. Inc. increased its holdings in Sarepta Therapeutics by 125.0% in the 1st quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 125 shares in the last quarter. Central Pacific Bank Trust Division acquired a new stake in Sarepta Therapeutics in the 1st quarter valued at $414,000. Nordea Investment Management AB increased its holdings in Sarepta Therapeutics by 120.6% in the 1st quarter. Nordea Investment Management AB now owns 61,657 shares of the biotechnology company’s stock valued at $8,004,000 after purchasing an additional 33,711 shares in the last quarter. Finally, Connecticut Wealth Management LLC acquired a new stake in Sarepta Therapeutics in the 1st quarter valued at $261,000. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.